15.361 articles found

DETERMINATION OF OPTIMAL VIBRATION DOSE TO TREAT PARKINSON’S DISEASE GAIT SYMPTOMS: A CLINICAL TRIAL

Check source for author details

Innovation in aging · 2023-12-01

ASSESSING THE UPTAKE OF CORE OUTCOME SETS IN RANDOMIZED CONTROLLED TRIALS FOR PARKINSON’S DISEASE

Check source for author details

Innovation in aging · 2023-12-01

Probabilistic graphical modelling using Bayesian networks for predicting clinical outcome after posterior decompression in patients with degenerative cervical myelopathy.

Shin DA, Lee SH, Oh S, Yoo C, Yang HJ, Jeon I, Park SB.

Ann Med · 2023-12-01

DOI: 10.1080/07853890.2023.2232999PMID: 37435966

Advanced biological ageing predicts future risk for neurological diagnoses and clinical examination findings.

McMurran CE, Wang Y, Mak JKL, Karlsson IK, Tang B, Ploner A, Pedersen NL, Hägg S.

Brain · 2023-12-01

DOI: 10.1093/brain/awad252PMID: 37490842

How should we be using biomarkers in trials of disease modification in Parkinson's disease?

Vijiaratnam N, Foltynie T.

Brain · 2023-12-01

DOI: 10.1093/brain/awad265PMID: 37536279

A novel transcranial photobiomodulation device to address motor signs of Parkinson's disease: a parallel randomised feasibility study.

Herkes G, McGee C, Liebert A, Bicknell B, Isaac V, Kiat H, McLachlan CS.

EClinicalMedicine · 2023-12-01

DOI: 10.1016/j.eclinm.2023.102338PMID: 38094162

Clinical profile of levodopa-carbidopa-entacapone intestinal gel infusion in patients with advanced Parkinson's disease.

Atanasova-Ivanova KA, Hristova-Chakmakova SI, Milanov IG.

Folia Med (Plovdiv) · 2023-12-01

DOI: 10.3897/folmed.65.e108196PMID: 38351782

Setting the clinical context to non-motor symptoms reflected by Park-pain, Park-sleep, and Park-autonomic subtypes of Parkinson's disease.

Qamar MA, Tall P, van Wamelen D, Wan YM, Rukavina K, Fieldwalker A, Matthew D, Leta V, Bannister K, Chaudhuri KR.

Int Rev Neurobiol · 2023-12-01

DOI: 10.1016/bs.irn.2023.08.012PMID: 38341227

The effects of Brazilian dance, deep-water exercise and nordic walking, pre- and post-12 weeks, on functional-motor and non-motor symptoms in trained PwPD.

Haas AN, Delabary MDS, Passos-Monteiro E, Wolffenbuttel M, Donida RG, Casal MZ, Zanardi APJ, Rodrigues LP, Martinez FG, Peyré-Tartaruga LA.

Arch Gerontol Geriatr · 2023-11-30

DOI: 10.1016/j.archger.2023.105285PMID: 38056105

Effects of facial biofeedback on hypomimia, emotion recognition, and affect in Parkinson's disease.

Roßkopf S, Wechsler TF, Tucha S, Mühlberger A.

J Int Neuropsychol Soc · 2023-11-29

DOI: 10.1017/s1355617723000747PMID: 38017615

Freezing of gait in Parkinson's disease with glucocerebrosidase mutations: prevalence, clinical correlates and effect on quality of life.

Ou R, Li C, Wei Q, Liu K, Lin J, Yang T, Xiao Y, Jiang Q, Cheng Y, Hou Y, Zhang L, Song W, Chen X, Lai X, Shang H.

Front Neurosci · 2023-11-28

DOI: 10.3389/fnins.2023.1288631PMID: 38089969

NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease.

Berven H, Kverneng S, Sheard E, Søgnen M, Af Geijerstam SA, Haugarvoll K, Skeie GO, Dölle C, Tzoulis C.

Nat Commun · 2023-11-28

DOI: 10.1038/s41467-023-43514-6PMID: 38016950